According to the Center for Disease Control and Prevention (CDC), diabetes is the seventh leading cause of death among Americans.
The diabetes diagnosis treatment and drug deliver market in the U.S. is expanding rapidly due to the increasing number of diabetics and the boom in modern insulin, insulin pens, and their accessories.
This market will grow in conjunction with the number of diagnosed diabetics. Some segments will grow faster than others as the demand for modern and more efficient products is increasing faster than the rate of new diabetics. Conversely, reimbursement cuts and declining prices in some segments will affect the market negatively.
The U.S. diabetes diagnosis, treatment and drug delivery market by segment includes the traditional blood glucose meters, traditional blood glucose strips, lancets and lancing devices, continuous glucose monitoring (CGM), insulin pump and supplies, modern insulin (vials, pens and cartridges), insulin syringe and pen needles. Visit for a full list of sub-segments.
The key markets to watch include the modern insulin market, the insulin pump and supplies market and the continuous glucose monitoring market.
2013 Segment Numbers include:
- Insulin Syringe Market: $374 million
- Continuous Glucose Monitoring (CGM) Market: $256 million
- Traditional Blood Glucose Strip Market: $3.2 billion
- Modern Insulin Market (Vials, Pens and Cartridges): $10.7 million
For information on this report please request a free table of contents for the U.S. Diabetes Diagnosis, Treatment and Drug Delivery Market.
Companies included in this report are: Sanofi, Medtronic, Novo Nordisk, Eli Lilly, LifeScan, Roche, Becton Dickinson, Bayer, Abbott, Nipro Diagnostics, Insulet Corporation, Animas, DexCom, Nova, Covidien, Owen Mumford, Valeritas, ACON Laboratorie, Allison Medical, ApexBio, Arkray, Medline and Tandem Diabetes.